+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Topical treatment with nanoliposomal Amphotericin B reduces early lesion growth but fails to induce cure in an experimental model of cutaneous leishmaniasis caused by Leishmania mexicana



Topical treatment with nanoliposomal Amphotericin B reduces early lesion growth but fails to induce cure in an experimental model of cutaneous leishmaniasis caused by Leishmania mexicana



Acta Tropica 173: 102-108



Leishmania mexicana infection causes localized skin lesions that can lead to tissue damage and permanent disfigurement if not resolved. Currently, recommended treatments include intravenous administration of Amphotericin B, which is undesirable due to the associated cost and patient burden related to receiving regular injections. In this study, we evaluated the effect of topical treatment with a nanoliposomal formulation of Amphotericin B that is penetrable to the skin (SinaAmphoLeish 0.4%) in mice infected with L. mexicana by using ulcerated (BALB/c) and non-ulcerated (129SVE) models. BALB/c mice received a 4 week treatment following ulcerated lesion development, while 129SVE mice received a 10 week treatment beginning at week 5 post-infection. Although mice from both models showed comparable susceptibility to L. mexicana infection after topical treatment with SinaAmphoLeish relative to controls, 129SVE mice displayed a transient decrease in lesion sizes which eventually became similar to control mice. On other hand this treatment resulted in no reduction in the lesion sizes in BALB/c mice. 129SVE treated mice exhibited greater IFN-γ, IL-4, and IL-10 cytokine levels and higher T-cell proliferation in re-stimulated draining lymph node cells. BALB/c mice showed no differences in cytokine responses between treated and control mice. These findings indicate that topical SinaAmphoLeish treatment is not likely to be effective in the treatment of cutaneous leishmaniasis caused by L. mexicana.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 060408524

Download citation: RISBibTeXText

PMID: 28602835

DOI: 10.1016/j.actatropica.2017.06.004


Related references

Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis. Antimicrobial Agents and ChemoTherapy 53(12): 5108-5113, 2009

Pentalinon andrieuxii root extract is effective in the topical treatment of cutaneous leishmaniasis caused by Leishmania mexicana. PhytoTherapy Research 28(6): 909-916, 2014

Preliminary study towards a novel experimental model to study localized cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana. Revista do Instituto de Medicina Tropical de Sao Paulo 54(3): 165-169, 2012

Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment. American Journal of Tropical Medicine and Hygiene 75(6): 1074-1077, 2006

Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals. Antimicrobial Agents and ChemoTherapy 26(5): 745-751, 1984

Topical treatment of cutaneous leishmaniasis in Belize: in vitro and in vivo studies with Leishmania mexicana. International Journal for Parasitology 23(1): 121-127, 1993

Experimental cutaneous leishmaniasis. 3. Comparative pathology of infection by Leishmania brazilensis, Leishmania mexicana, and Leishmania tropica in laboratory animals. Revista do Instituto de Medicina Tropical de Sao Paulo 14(1): 12-29, 1972

Inbred mice as model hosts for cutaneous leishmaniasis 1. resistance and susceptibility to infection with leishmania braziliensis leishmania mexicana and leishmania aethiopica. Annals of Tropical Medicine and Parasitology 78(1): 25-34, 1984

Inefficacy of the association N-methyl glucamine and topical miltefosine in the treatment of experimental cutaneous leishmaniasis by Leishmania (Leishmania) amazonensis. Journal of Venomous Animals and Toxins including Tropical Diseases 13(3): 598-606, 2007

Treatment of two patients with diffuse cutaneous leishmaniasis caused by Leishmania mexicana modifies the immunohistological profile but not the disease outcome. Tropical Medicine and International Health 4(12): 801-811, 1999

Experimental cutaneous leishmaniasis. II. The pathology of leishmaniasis by Leishmania mexicana. Revista do Instituto de Medicina Tropical de Sao Paulo 7(3): 145-155, 1965

Draft Genome Sequences of Leishmania ( Leishmania ) amazonensis , Leishmania ( Leishmania ) mexicana , and Leishmania ( Leishmania ) aethiopica , Potential Etiological Agents of Diffuse Cutaneous Leishmaniasis. Microbiology Resource Announcements 8(20):, 2019

Ox40L-Ox40 pathway plays distinct roles in regulating Th2 responses but does not determine outcome of cutaneous leishmaniasis caused by Leishmania mexicana and Leishmania major. Experimental Parasitology 148: 49-55, 2015

Cutaneous leishmaniasis caused by Leishmania mexicana amazonensis in Panama. Revista Medica de Panama 13(1): 158-164, 1988

The experimental chemo therapy of leishmaniasis 6. the development of rodent models for cutaneous infection with leishmania major and leishmania mexicana amazonensis. Annals of Tropical Medicine and Parasitology 74(3): 299-320, 1980